Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study
Why the study?
Does nadroparin reduce symptomatic thromboembolic events in cancer outpatients receiving chemotherapy?
Population
1,150 cancer outpatients receiving chemotherapy
Comparison
Subcutaneous injections of nadroparin vs Placebo
Design
Cohort, Randomly assigned
Authors
Discussion
Loading...
Member takes
Implication
May support thromboprophylaxis in gemcitabine regimens; hypothesis-generating and leaves open RCT confirmation before practice change.
Structured PICO
Does nadroparin reduce symptomatic thromboembolic events in cancer outpatients receiving chemotherapy?
P
Population
1,150 cancer outpatients receiving chemotherapy
I
Intervention
Subcutaneous injections of nadroparin
C
Comparator
Placebo
O
Outcome
Incidence of symptomatic thromboembolic events (TEs)hard clinical
Nadroparin thromboprophylaxis significantly reduces the risk of thromboembolic events in cancer outpatients receiving high-risk chemotherapy regimens such as gemcitabine and platinum analogues.
Cite This Study
Barni et al. (2011) studied this question.